[#item_full_content]
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #BreastCancer–Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced a poster for preclinical data on CID-078, a first-in-class oral macrocycle cyclin A/B RxL inhibitor, will be presented at the San Antonio Breast Cancer Symposium 2024. The event, which runs from December 10-13, brings together global leaders in breast cancer research and treatment. Poster present